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Abstract
Purpose: The potential prognostic value of survivin in resected non-small cell lung carcinoma (NSCLC) is variably reported.
The objective of this study was to conduct a systematic review of literatures evaluating survivin expression in resected
NSCLC as a prognostic indicator.
Methods: Relevant literatures were identified using PubMed, EMBASE and Chinese Biomedicine Databases. We present the
results of a meta-analysis of the association between survivin expression and overall survival (OS) in NSCLC patients. Studies
were pooled and summary hazard ratios (HR) were calculated. Subgroup analyses and publication bias were also conducted.
Results: We performed a final analysis of 2703 patients from 28 evaluable studies. Combined HRs suggested that survivin
overexpression had an unfavorable impact on NSCLC patients’ survival with no evidence of any significant publication bias
(HR=2.03, 95%CI: 1.78–2.33, Egger’s test, P=0.24) and no severe heterogeneity between studies (I
2=26.9%). Its effect also
appeared significant when stratified according to the studies categorized by histological type, HR estimate, patient race,
cutoff point (5%, 10%), detection methods and literature written language except for disease stage. Survivin was identified
as a prognostic marker of advanced-stage NSCLC (HR=1.93, 95%CI: 1.49-2.51), but not early-stage NSCLC (HR=1.97, 95%CI:
0.76-5.14), in spite of the combined data being relatively small.
Conclusion: This study shows that survivin expression appears to be a pejorative prognostic factor in terms of overall
survival in surgically treated NSCLC. Large prospective studies are now needed to confirm the clinical utility of survivin as an
independent prognostic marker.
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Introduction
Lung cancer is the leading cause of death from cancer around
the world, accounted for an estimated 157,300 deaths in the
United States in 2010 [1]. Non–small cell lung carcinoma
(NSCLC) accounted for approximately 85% of the cases [2].
Despite recent advances made in clinical and experimental
oncology, the prognosis of lung cancer is still unfavorable, with a
5-year overall survival rate of only around 11% [3]. Several
independent prognostic factors for survival in NSCLC patients
have been identified: performance status, disease stage, age, sex,
and amount of weight lost [4]. The most important prognostic
factor for survival is tumor stage, primarily because early stage
disease is amenable to completely surgical resection, hopefully
before the tumor cells have acquired the ability to metastasize.
However, even in the early stage of the disease, about 30% of
patients suffer from relapse and die within 5 years of surgery [5].
Although these prognostic parameters do reflect biological features
of both tumor and patient, they do not allow adequate prediction
of outcome for the individual patient. The discovery of molecular
biological prognostic factors should aid in a more accurate
prediction of clinical outcome and may also reveal novel predictive
factors and therapeutic targets [6]. Hundreds of studies have
evaluated prognostic markers that have an association with some
clinical outcome, typically overall or recurrence-free survival in
lung cancer. Of these, the three important pathways in lung
cancer: cell cycle regulation, apoptosis, and angiogenesis are
widely investigated.
Survivin also called baculoviral inhibitor of apoptosis repeat-
containing 5 (BIRC5) is a member of the inhibitor of apoptosis
(IAP) family, which is one of the most cancer-specific proteins
identified to date, being unregulated in almost all human tumors.
Biologically, survivin has been shown to inhibit apoptosis, enhance
proliferation and promote angiogenesis [7–9], which is expressed
highly in most human tumors and fetal tissue, but is undetectable
in most terminally differentiated cells [10]. Because of larger
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its causal role in cancer development, survivin is currently
attracting considerable attention as a cancer prognostic indicator
and a new target for anti-cancer therapies. Strategies under
investigation to target survivin include antisense oligonucleotides,
siRNA, ribozymes, immunotherapy and small molecular weight
molecules (for review, see Refs.[11]). The translation of these
findings to the clinic is currently ongoing with a number of phase
I/II clinical trials targeting survivin in progress.
The expression of survivin has been reported to be a promising
prognostic indicator, associated with a worse overall survival.
However, evidence regarding the prognostic value of survivin
with respect to overall survival in NSCLC remains controversial.
In order to clarify this question, we performed this systematic
review of the literatures with methodological assessment and
meta-analysis.
Results
Literature Selection and Characteristics
A total of 317 potentially relevant citations were retrieved after
initial databases search. The title and abstract of relevant articles
were read by two authors independently. Two hundred and
seventy-three citations were excluded from analysis after the first
screening based on abstracts or titles, leaving 44 available for
further full text review. After carefully reading the full text articles,
6 were excluded because they were reviews instead of observa-
tional studies. Five were excluded because they investigated the
correlation with clinicopathological variables not survivals.
Meanwhile, another 4 studies were excluded due to lacking of
sufficient survival data. Additionally, 2 studies were found by hand
search of the reference lists. As a result, 31 eligible studies
including 2984 NSCLC cases were included in this meta-analysis
[12–42]. The basic feature descriptions of the 31 studies are
summarized in Table 1. Briefly, study sample sizes ranged from 43
to 219, 23 studies were conducted in Asian populations, while
others were European populations. Twenty-five studies reported
two or more subtypes of NSCLC, while 4 were about
adenocarcinoma only. Fifteen studies were of I–III stage and 7
were of all stages. Most of the studies investigated survivin by IHC
(24 studies), 6 studies using reverse transcription-polymerase chain
reaction (RT-PCR), only one study identified survivin by
fluorescence in situ hybridization (FISH) [38]. In addition, all
the studies investigated survivin expression using lung cancer
tissues except one study which detected the expression with
circulating cancer cells [23].Twenty-four studies reported survivin
as an indicator of poor prognosis, while the other seven studies
showed no significant impact on overall survival.
Quality Assessment
Overall, the global quality score of the included studies ranged
from 44.6 to 62.0% with a mean of 55.2% (as Table 2 shows).
Concerning the global score, there was no statistically significant
difference between the 24 positive and the 7 negative trials (mean
of 54.4% versus 55.2%, p=0.67). There was no statistical
difference in global score between studies that performed on
Asian (n=22) or non-Asian populations (n=9), with scores of
51.6% and 54.5%, respectively (p=0.25). Moreover, there was no
significant disparities for the effective value of overall survival was
determined (HR: 54.0%, Sur. Curve: 52.6%, p=0.39).The
absence of a significant quality difference between significant
and non-significant studies made it possible to perform this
quantitative aggregation of the survival results.
Assessment of heterogeneity and meta-analysis
Highly significant heterogeneity was detected when all studies
were pooled (chi-squared=110.45, I
2=71.9%, p,0.001), then
the source of heterogeneity was explored using meta-regression
analysis. One study investigated survivin expression by FISH [38],
one study failed to report time-to-event data directly [33] and one
study investigated survivin in only stage I NSCLC [40] were the
main source of heterogeneity. After excluding them, the
heterogeneity dropped sharply with no significant changes to the
summary HR (chi-squared=38.32, I
2=26.9%, p=0.092). In
order to make a conservative estimate, random-effects meta-
analyses were used to account for interstudy heterogeneity and to
summarize the prognostic value of survivin across studies.
After excluding the 3 studies, the meta-analysis was performed on
the 28 remaining studies. The main results of this meta-analysis are
presented in Table 3. Overall, the pooled HR for all evaluable
studies evaluated survivin expression in NSCLC was 2.03 (95%CI:
1.78–2.33). No individual studies influence the summary HR found
by one-way sensitivity analysis, indicating that survivin overexpres-
sion was an indicator of poor prognosis for NSCLC patients.
When grouped according to the ethnicity, the combined HRs of
Asian studies and non-Asian studies were 2.07 (95%CI: 1.75–2.44)
and 1.95 (95% CI: 1.51–2.53), respectively. In the subgroup
analysis according to the method of survivin detection used, the
combined HR was 2.16 (95%CI: 1.87–2.49) for IHC and 1.62
(95%CI: 1.21–2.16) for RT-PCR. When stratified according to
literature written language, the combined HRs of both English
and non-English literatures showed an inverse effects on survival
(HR=1.93 and 2.31, separately). Although we also observed
statistically significant effects of survivin expression on survival
from studies reported all stages with an HR of 2.13 (95% CI: 1.57–
2.89) and from 15 studies reported stage I–III with an HR of 2.07
(95% CI: 1.72–2.48), when we aggregated the studies that
reported results for early-stage and advanced-stage NSCLC, the
combined HR were 1.97 (95% CI: 0.76–5.14) and 1.93 (95%
CI:1.49–2.51) with 3 and 4 studies in each arms, respectively
(Figure 1). Furthermore, we aggregated the studies separately
according to histological subgroups, the summary HR of the
studies investigated NSCLC as a whole was 1.82 (95% CI: 1.48–
2.23). The combined HRs were 2.50 (95% CI: 1.67–3.73) and
2.24 (95% CI: 1.83–2.75) based on four studies of adenocarcinoma
and nine of squamous cell carcinoma and adenocarcinoma,
respectively. When the HRs derived from Cox regression analysis
of the 21 evaluable studies were aggregated, the combined HR was
2.01 (95% CI: 1.71–2.37). It indicated that survivin was an
independent prognostic marker in resected NSCLC. Moreover,
when the survival data calculated indirectly from Kaplan-Meier
based survival curve were pooled, the combined HR was 2.13
(95% CI: 1.65–2.74), also suggesting survivin status was of
prognostic value (Figure 2). Finally, grouped according to the
positive threshold for survivin expression, as defined by the studies’
authors, the combined HRs of 5% and 10% cutoff value were 2.66
(95% CI: 2.05–3.47) and 1.84 (95% CI: 1.44–2.36), separately.
Publication bias
The Egger’s test and Begg’s funnel plot wereappliedfor detecting
publication bias in the meta-analysis. In all included studies, no
funnel plot asymmetry was found, with p=0.24 in the Egger’s test
(Figure 3). So, there is no evidence of publication bias detected.
Discussion
Survivin, as a biomarker of prognosis in malignancies, has
generated much interest. But the conclusions for its prognostic
Survivin and NSCLC Prognosis
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prognostic indicator in esophageal, hepatocellular, and ovarian
cancers, cholangiocarcinoma, and endometrial cancers. In con-
trast, favorable outcome associated with nuclear survivin has been
reported for gastric, bladder, and breast cancers, ependymoma,
osteosarcoma and pancreatic ductal adenocarcinoma [43,44]. The
differences in the prognostic value of survivin for NSCLC patients
were also observed. Although one meta-analysis had been reported
on the prognostic value of survivin in NSCLC previously [45], the
authors ignored five [30,32,34,37,41] valuable studies at the time
of literature searching. Furthermore, the effect size was evaluated
by relative risk (RR), which measured only the number of events
and took no account of when they occur are appropriate for
measuring dichotomous outcomes, but less appropriate for
analyzing time-to-event outcomes [46]. With a larger sample size
acquired and appropriate method to aggregate the individual data,
a meta-analysis to veritably evaluate the role of survivin in the
prognosis of non-small cell lung cancer was performed.
The level of evidence provided by retrospective studies regarding
prognostic indicators is lower than provided by randomized
controlled trials. Our study used data from published trials rather
than individual patient data. Although no evidence for significant
heterogeneity was found, it is possible that the results of the meta-
analysis could have been influenced by differences between the 28
studies. Studies may have differed with regard to the baseline
characteristics of the patients included (age, histological type,
differentiation or disease stage), the adjuvant treatment they might
have received, the duration of follow-up and adjustments for other
cofactors. Therefore, we attempted to perform a stratified subgroup
analysis. As a result, the meta-analysis based on 31 literatures shows
that the expression of the survivin protein is a poor prognostic factor
for the survival of NSCLC who underwent surgical resection.
Table 1. Characteristics and results of eligible prognostic studies evaluating surviving.
First Author Year
Source of
Patients
N. of
Patient Histology Method Stage
N. of
Positive
Cutoff
value
HR
Estimate HR 95%CIs
Kim [12] 2011 South Korea 151 SCC TMA I–IV 116 5% HR 2.05 1.15–3.58
93 ADC TMA I–IV 62 5% HR 4.51 1.71–11.93
Zhang Q [13] 2010 China 74 ADC IHC I–III 25 10% HR 2.16 1.37–3.75
Zhang JR [14] 2010 China 60 SCC&ADC IHC I–III 56 5% HR 2.94 1.89–4.57
Yang [15] 2010 China 60 SCC&ADC TMA I–IV 31 5% Sur. Curve 1.86 1.09–3.78
Weng [16] 2010 China 50 NSCLC IHC I–III 39 NA HR 5.22 1.20–22.61
Porebska [17] 2010 Poland 74 NSCLC IHC I–IV 39 20% Sur. Curve 0.98 0.28–3.44
Nakashima [18] 2010 Japan 122 NSCLC IHC I–IIIB 64 25% HR 2.13 1.49–3.03
Lv [19] 2010 China 70 SCC&ADC IHC I–III 52 30% HR 4.02 1.73–9.39
Grossi [20] 2010 USA 87 NSCLC TMA IIIA–N2 62 50% HR 1.61 0.94–2.77
Dai [21] 2010 China 66 NSCLC RT-PCR IB–IIIA 33 0.413 HR 1.493 1.12–2.13
Chen [22] 2010 China 72 NSCLC RT-PCR IIIB–IV 36 0.467 HR 2.12 1.22–3.11
Yie [23] 2009 China 78 SCC&ADC RT-PCR I–IV 33 1.02 HR 1.51 1.06–3.63
Yamashita [24] 2009 Japan 47 NSCLC RT-PCR I–III 28 NA HR 0.62 0.22–1.75
Mohamed [25] 2009 Japan 78 NSCLC IHC IIIA–N2 68 10% HR 2.21 1.26–3.89
Hoshil [26] 2009 Japan 100 SCC&ADC IHC I–IIIB 76 10% HR 1.73 1.04–2.97
Chen [27] 2009 China 80 ADC IHC III–IV 41 10% Sur. Curve 1.81 1.05–3.13
Li [28] 2008 China 91 SCC&ADC IHC I–III 46 10% HR 1.87 1.04–3.34
Bria [29] 2008 Italy 116 NSCLC IHC I–IIIA 82 20% HR 1.83 1.01–3.30
Zhu [30] 2007 China 213 NSCLC IHC I–II 43 10% HR 0.80 0.41–1.55
Yoo [31] 2007 Korea 219 NSCLC IHC I–IIIA 6 10% HR 1.12 0.35–3.54
Wang [32] 2006 China 115 NSCLC IHC I–II 72 5% HR 3.73 1.66–8.39
Vischioni [33] 2006 Netherlands 138 NSCLC IHC I–IIIA 127 5% Logrank +p 0.78 0.49–1.26
Atikcan [34] 2006 Turkey 58 SCC&ADC IHC I–IIIA 28 25% HR 3.73 1.53–9.05
Akyurek [35] 2006 Turkey 78 NSCLC IHC I–IV 50 10% Sur. Curve 2.28 1.17–4.43
Zhou [36] 2005 China 43 SCC&ADC IHC I–III 34 5% Sur. Curve 3.14 1.27–9.78
Shinohara [37] 2005 USA 144 NSCLC IHC I–II 105 25% HR 2.74 1.29–5.79
Karczmarek [38] 2005 Poland 60 NSCLC FISH IIB–III 35 NA HR 4.27 3.51–5.03
Kren [39] 2004 USA 102 SCC&ADC IHC I–IIIA 54 15% Sur. Curve 2.16 1.34–3.44
Falleni [40] 2003 Italy 83 NSCLC RT-PCR I 44 25n Sur. Curve 0.86 0.53–1.37
Ikehara [41] 2002 Japan 79 ADC IHC I–IV 41 10% Sur. Curve 4.16 1.60–10.30
Monzo [42] 1999 Spain 83 NSCLC RT-PCR I–IIIA 71 NA HR 2.20 1.10–4.50
N., number; ADC, adenocarcinoma; SCC, squamous cell carcinoma; NSCLC, non-small cell lung cancer; IHC, immunohistochemistry; TMA, tissue microarray; FISH,
fluorescence in situ hybridization; RT-PCR, reverse transcription-polymerase chain reaction; NA, not applicable; HR, hazard ratio; Sur. Curve, survival curve.
doi:10.1371/journal.pone.0034100.t001
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stagesofNSCLC,the association wasalsofound instage III–IV,but
not stage I–II, indicating that survivin could probably predict worse
prognosis in advanced-stage NSCLC. In particular, an important
issue that we need to take into account is the type of adjuvant
therapy that each patient received after resection because
chemotherapy and/or therapies that target the epidermal growth
factor receptor, such as gefitinib or erlotinib, can change the
Table 2. Results of the methodological assessment by the European Lung Cancer Working Party score.
Number of studies Global Score (%) Design(/10) Laboratory methodology(/10) Generalizability(/10) Results analysis(/10)
All studies 31 55.2 5.4 5.7 5.3 5.2
Positive 24 54.4 5.3 5.4 5.5 5.0
Negative 7 55.2 5.4 6.1 5.2 5.4
p 0.67 0.76 0.42 0.12 0.66
Asian 22 51.6 4.9 4.8 5.0 4.9
Non-Asian 9 54.5 5.6 5.3 5.2 5.5
p 0.25 0.09 0.32 0.26 0.34
HR 22 54.0 5.6 5.6 5.4 5.3
Sur. curve 8 52.6 4.8 5.3 5.2 4.8
p 0.39 0.028 0.65 0.14 0.08
Score distributions are summarized by the median values; Negative, no significant prognostic factor for survival; Positive, as significant poor prognostic factor for
survival; HR, Hazard ratio.
doi:10.1371/journal.pone.0034100.t002
Table 3. Summarized HRs of overall and subgroup analyses for survivin on NSCLC survival.
N. of studies Number of patients Random effects HR(95%CIs) Heterogeneity test
chi-squared I
2 P-value
Overall 28 2703 2.03 (1.78–2.33) 38.32 26.9% 0.092
Written Language
English written 19 1929 1.93 (1.69–2.21) 20.18 5.8% 0.384
Non English written 9 776 2.31 (1.66–3.21) 16.57 51.7% 0.035
HR Estimate
HR 21 2207 2.01 (1.71–2.37) 33.49 37.3% 0.041
Sur. Curve 7 516 2.13 (1.65–2.74) 4.58 0.00% 0.599
Histological type
ADC 4 326 2.50 (1.67–3.73) 4.16 27.9% 0.247
ADC&SCC 9 662 2.24 (1.83–2.75) 8.24 2.90% 0.410
NSCLC 15 1565 1.82 (1.48–2.23) 21.84 35.9% 0.082
Methods
IHC 23 2297 2.16 (1.87–2.49) 28.06 18.0% 0.214
RT-PCR 5 346 1.62 (1.21–2.16) 5.59 28.5% 0.232
Ethnicity
Asian 22 2097 2.07 (1.75–2.44) 35.51 38.1% 0.034
Non-Asian 6 606 1.95 (1.51–2.53) 2.76 0.00% 0.736
Tumor stage
I–II 3 472 1.97 (0.76–5.14) 10.08 80.2% 0.006
I–III 15 1301 2.07 (1.72–2.48) 19.73 29.0% 0.139
I–IV 6 613 2.13 (1.57–2.89) 7.18 16.5% 0.304
III–IV 4 317 1.93 (1.49–2.51) 0.86 0.00% 0.836
Cutoff value
5% 6 522 2.66 (2.05–3.47) 4.17 0.00% 0.525
10% 9 1012 1.84 (1.44–2.36) 11.01 27.3% 0.201
N., number; HR, hazard ratio; NSCLC, non-small cell lung cancer. ADC, adenocarcinoma; SCC, squamous cell carcinoma;
doi:10.1371/journal.pone.0034100.t003
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especially targeted therapies may influence the survival of NSCLC.
However, the majority of published studies lacked detail regarding
patient treatment. All these sources of variability could produce
additional inconsistencies and cause potential selection bias.
Therefore, our results need to be substantiated by further
prospective studies.
We also performed a methodological assessment of the studies
to avoid some selection biases (more detailed reports of significant
trials) according to ELCWP scale. The absence of a detectable
difference in quality score between significant and non-significant
studies encourages us to perform a quantitative aggregation of the
results of the individual trials. But this meta-analysis had to deal
with heterogeneity problems. There was a highly significant
heterogeneity among the 31 evaluable studies. Meta-regression
analysis according to the type of patients, the disease character-
istics, and the diversity in the techniques used to identify survivin
status detected 3 studies accounting for the heterogeneity.
The heterogeneity could be explained by the fact that the
technique of detecting survivin is not comparable among the
studies. Most studies (77.4%) in the meta-analysis used IHC
staining to study expressions of survivin. Although IHC staining is
simple and cost-effective to perform, results are highly dependent
on a variety of methodological factors, such as storage time,
fixation method of paraffin-embedded tissues, different primary
antibodies, the revelation protocols and different levels of positive
(0, 10, 50%, different scores combining intensity and percentage,
intensity only) [48]. Traditional survival analysis techniques
(Kaplan–Meier, log-rank test) rely on variable dichotomization
into high or low values or splits into multiple bins. Immunostaining
cutoff point were arbitrarily selected and varied between studies.
So, variability in protein expression assessment must be considered
a potential source of bias. Only three studies [12,15,20] identified
survivin using tissue microarray highlighted the importance of this
high-throughput methodology allowing appropriate tissue re-
source rationing but also improving IHC standardization and
reproducibility in large cohorts. In addition, the use of the recently
published REMARK guidelines for reporting of prognostic factor
studies will aid in a more complete and transparent reporting [49],
thereby also increasing the number of high-quality studies that can
be included in a meta-analysis.
Finally, the pooled HRs calculated in our meta-analysis may
be overestimated due to publication and reporting bias. We
attempted to minimize publication bias by performing the
literature search as complete as possible, using PubMed, EMBASE
and Chinese Biomedicine databases. However, we did not take
unpublished papers and abstracts into account because the
required data was unavailable. Positive results tend to be more
acceptable by journals, whereas negative results often are rejected
or are not even submitted for review. Of the studies investigating
survivin expression in patients with NSCLC, 4 were not included
in the meta-analysis due a lack of available, or calculated, survival
Figure 1. The association between survivin overexpression and overall survival of NSCLC stratified by tumor stage. The summary HR
and 95% CIs were shown (according to the random effect estimations).
doi:10.1371/journal.pone.0034100.g001
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used to extrapolate the HR. If the HR was not reported in a study,
it was calculated from the data included in the article or
extrapolated from the survival curves. In fact, the method of
extrapolating HR from survival curves did seem to be less reliable
than when it was obtained from published statistics because this
strategy did not completely eliminate inaccuracy in the extracted
survival rates. In addition, each study adjusted for different
covariates and only the studies that found significant results in
univariate analysis performed multivariate analysis, thus pooling of
results may produce bias. Language also introduces bias, and
positive results tend to be published in English-language journals.
Although our search was conducted without language restriction,
only one study written in a Japanese language was included except
for Chinese and English articles in the meta-analysis [26].
Nevertheless, no publication bias was detected using Egger’s test,
suggesting that the statistics obtained approximate the actual
results.
In conclusion, survivin expression was associated with a poor
prognosis in patients with NSCLC in the present systematic review
with meta-analysis. Interestingly, our meta-analysis suggests that
survivin has a detrimental effect on survival in stage III–IV
NSCLC. Survivin expression as a prognostic tool at the advanced
stage of NSCLC may help clinicians to make difficult therapeutic
decisions. Our conclusions need to be confirmed by an adequately
designed prospective study and the exact role of survivin
expression needs to be determined by an appropriate multivariate
analysis taking into account the classical well-defined prognostic
factors for lung cancer.
Materials and Methods
Search strategy and selection criteria
Studies were identified via an electronic search of PubMed,
EMBASE and Chinese Biomedicine Databases using the following
keywords: non-small cell lung carcinoma, NSCLC, BIRC5,
baculoviral inhibitor of apoptosis repeat-containing 5, survivin,
prognostic, prognosis and survival. The search ended on June
2011. The meta-analysis gathered complete databases from
published studies dealing with the prognostic value of survivin in
Figure 2. The association between survivin overexpression and overall survival of NSCLC stratified by HR estimation. The summary
HR and 95% CIs were shown (according to the random effect estimations).
doi:10.1371/journal.pone.0034100.g002
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No language of published papers was restricted. To be eligible for
inclusion, studies had to meet the following criteria: (i)they
measured survivin expression in NSCLC with immunohistochem-
istry (IHC), reverse transcription- polymerase chain reaction (RT-
PCR) or fluorescence in situ hybridization (FISH); (ii) compared of
overall survival between different expressions of survivin in
NSCLC; (iii) hazard ratios (HRs) for overall survival according
to survivin status either had to be reported or could be computed
from the data presented; (iv) when the same author or group
reported results obtained from the same patient population in
more than one article, the most recent report or the most
informative one was included. We also used a manual reference
search for relevant articles, including original articles and reviews,
to identify additional studies. Abstracts were excluded because of
insufficient data for use. To avoid duplication of data, we carefully
noted the author names and the different research centers
involved.
Data extraction
Data were extracted independently by two investigators (Zhang
L.Q. and Jiang F.) by means of a predefined form. Topics in this
form were first author’s surname, year of publication, patient race,
number of patients, histological type, disease stage, assay method,
Figure 3. Funnel plots of Begg’s and Egger’s were used to detect publication bias on overall estimate. Studies are distributed
symmetrically above and below the horizontal line, and suggest that the meta-analysis is absence of publication bias.
doi:10.1371/journal.pone.0034100.g003
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discrepancies were resolved by a meeting called by Xu L.
Assessment of study quality
Study quality was assessed independently by two investigators
(Zhang L.Q. and Xu L.) by means of reading and scoring each
study according to the European Lung Cancer Working Party
(ELCWP) scale established by Steels et al [50]. Briefly, each item
of the score was assessed using an ordinal scale (possible values 2,
1, and 0). The overall score assessed several dimensions of
methodology, grouped into four main categories: (i) the scientific
design; (ii) the description of the methods used to identify the
abnormal of survivin; (iii) the generallizability of the results; and
(iv) the analysis of the study data. Each category had a maximal
score of 10 points with an overall maximum theoretical score of 40
points. When an item was not applicable to a study, its value was
not taken into account in the total for the category. The final
scores were expressed as percentages, with higher values reflecting
a better methodological quality.
Definition of outcomes and comparisons
The primary outcomes were the overall survival in all
population and then stratified by histological type, ethnicity, stage,
test method, cutoff value, hazard ratio estimate and literature
written language. The effective value of overall survival was
determined by the combination of HR and 95% confidence
interval (CI). If a direct report of HR and 95% CI was not
available, estimated value was derived indirectly from other
presented data using the methods described by Tierney et al [46].
Two independent persons read the curves using Engauge Digitizer
version 2.11 (free software downloaded from http://digitizer.
sourceforge.net) to reduce inaccuracy in the extracted survival
rates.
Statistical analysis
The correlation between two continuous variables was mea-
sured by the Spearman rank correlation coefficient. Non-
parametric tests were used to compare the distribution of quality
scores according to the value of a discrete variable.
The combination of the estimated risk was obtained by
calculating the log (hazard ratio) and its variance estimates. A
combined HR.1 implied a worse survival for the group with
survivin overexpression. This pejorative impact of survivin on
survival was considered as statistically significant if the 95% CI for
the combined HR did not overlap 1. To assess heterogeneity
among the studies, we used the Cochran Q and I
2 statistics: for the
Q statistic, a P value,0.10 was considered statistically significant
for heterogeneity [51]; for I
2, a value.50% is considered a
measure of severe heterogeneity [52], then the random-effects
model was calculated according to the DerSimonian–Laird
method [53]. Otherwise, the fixed-effects model (Mantel–Haenszel
method) was used. The assessment of sources of heterogeneity was
undertaken by meta-regression analysis [54]. One-way sensitivity
analysis was performed to assess the stability of the results, namely,
a single study in the meta-analysis was deleted each time to reflect
the influence of the individual data set to the pooled HR [55]. A
funnel plot and Egger’s linear regression test were used to
investigate any possible publication bias [56]. For all analyses, a
two-sided P value less than 0.05 was considered to be statistically
significant. All analyses were performed using STATA version
11.0 software (Stata Corporation, College Station, TX).
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